EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT? P.S. Aisen J Prev Alz Dis 2019;6(3):150

EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE? J.C. Morris J Prev Alz Dis 2019;6(3):153-154

COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE Gauthier, J. Alam, H. Fillit, T. Iwatsubo, H. Liu-Seifert, M. Sabbagh, S. Salloway, C. Sampaio, J.R. Sims, B. Sperling, R. Sperling, K.A. Welsh-Bohmer, J. Touchon, B. Vellas, P. Aisen, and the EU/US/CTAD Task Force J Prev Alz Dis 2019;6(3):164-168

COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ? Bakchine J Prev Alz Dis 2019;6(3):174-176

COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALS Ballard, A. Corbett J Prev Alz Dis 2019;6(3):177-178

COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEP F. Jessen J Prev Alz Dis 2019;6(3):179

COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE E. Siemers J Prev Alz Dis 2019;6(3):180-181

En savoir plus : https://link.springer.com/journal/42414/6/3